Of note, lymphoid tumor cell lines (Ramos, HH, Jurkat, and CCRF-CEM) express the IL-7 receptor (CD127), albeit at levels lower than activated normal T cells (Supplemental Fig. 3), raising the possibility that a preponderant effect of rhIL-7-hyFc on tumor growth would outweigh any beneficial effect of rhIL-7-hyFc on UCART19 activity and tumor killing. Here, IL7R is linked to neoplasm.